tumour necrosis factor membrane form
别名 | TNFα, cachectin, necrosin |
---|---|
Compound Class | Peptide |
变动原因 |
TNFα is a pro-inflammatory, acute phase cytokine involved in systemic inflammation. The TNFSF2 precursor is also cleaved into a membrane-bound form of the ligand. |
Species |
Human |
Related Product | tumour necrosis factor membrane form |
Summary
基因/前体 |
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
是否批准为药物? | |||||||||||
IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
别名 | TNFα, cachectin, necrosin |
数据库链接
UniProtKB | P01375 |
---|---|
Wikipedia | Tumor_necrosis_factor-alpha |
RCSB PDB Structure | 1TNF |
Ensembl Gene | ENSG00000204490 |
DrugBank Target | P01375 |
CATH/Gene3D | 2.60.120.40 |
生物活性
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
---|---|
关联靶标 | tumor necrosis factor receptor 1 , tumor necrosis factor receptor 2 |
临床资料
作用机制与药效学效应 |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants |
---|
参考文献
1. Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, Harcourt K, Reckless J, MacDonald TT, Ray KP et al.. (2018) Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.. Sci Rep, 8 (1): (4941). [PMID:29563546] |
结构
Peptide Sequence | MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL |
---|---|
Post Translation Modifications | Predicted phosphorylation of serine residue at position 2; residues 19 and 20 are N6-myristoyl lysine |